ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Dallas, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Dallas, TX, USA:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Dallas, Texas, United States and 66 other locations

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting
Non Hodgkin Lymphoma
Drug: acalabrutinib
Drug: rituximab (IV)

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Dallas, Texas, United States and 31 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Dallas, Texas, United States and 39 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...

Active, not recruiting
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

Phase 2

Genmab
Genmab

Dallas, Texas, United States and 71 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: vinblastine
Drug: brentuximab vedotin

Phase 3

Takeda
Takeda

Dallas, Texas, United States and 215 other locations

with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy).Primary Therapeutic Objectives:* To improve the event-free su...

Active, not recruiting
Acute Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia
Drug: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Drug: Thioguanine

Phase 2, Phase 3

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Fort Worth, Texas, United States and 7 other locations

dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas...

Active, not recruiting
Lymphoma
Drug: HMPL-689

Phase 1

HUTCHMED
HUTCHMED

Dallas, Texas, United States and 26 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Dallas, Texas, United States and 56 other locations

2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma...

Enrolling
Refractory Primary Central Nervous System Lymphoma
Relapsed Primary Central Nervous System Lymphoma
Drug: Emavusertib
Drug: Ibrutinib

Phase 1, Phase 2

Curis

Dallas, Texas, United States and 42 other locations

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib...

Active, not recruiting
Lymphoma, Mantle-Cell
Drug: Ibrutinib
Drug: Pirtobrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Bedford, Texas, United States and 226 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems